Please login to the form below

enzalutamide

This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Pfizer/Astellas’ prostate cancer treatment Xtandi (enzalutamide) is also a prominent market competitor, with approvals in nmCRPC, mCSPC and metastatic castration-resistant prostate cancer (mCRPC).

Latest news

AZ/Merck's Lynparza improves survival in certain prostate cancers

In the key secondary endpoint of overall survival, Lynparza reduced the risk of death by 31% compared to enzalutamide or abiraterone. ... Lynparza is the only PARP inhibitor to demonstrate overall survival versus enzalutamide or abiraterone for men with
Bayer gets EU nod for prostate cancer drug Nubeqa

Astellas’ Xtandi (enzalutamide).
Givlaari, Rybelsus lead crowded CHMP recommendations

Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide).
J&J gets EMA nod for wider use of Erleada in prostate cancer

Erleada can now be used for mCSPC patients in combination with ADT in Europe ahead of Xtandi (enzalutamide), which was approved for this indication in December in the US but still
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).

More from news
Approximately 12 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Cost containment and the German market

The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive Salary

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Associate Account Director: Competitive Salary

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Senior Account Executive: Competitive Salary

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Medical Writer: Competitive Salary

Senior Content Editor - Biotechnology: Salary TBC

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Account Manager: Competitive Salary

No results were found

PMHub

Add my company

Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Empowering patients empowers results: Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials: What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training: Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...